login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

New imaging approach may assist in predicting success of treatment for AF


Thursday, 05 Mar 2009 10:34

University of Utah researchers have developed a magnetic resonance imaging (MRI)-based method for detecting and quantifying injury to the wall of the heart’s left atrium in patients who have undergone a procedure to treat atrial fibrillation. The results of the study were published in the Journal of the American College of Cardiology.
Previous research suggested scar formation within the left atrium (LA) after radiofrequency (RF) ablation helps to predict the success of the procedure in preventing the recurrence of atrial fibrillation.


"Until now, there has not been an accurate, non-invasive way to assess LA scar formation," said lead author Dr Nassir F Marrouche, assistant professor of internal medicine in the University of Utah School of Medicine and director of its Atrial-Fibrillation Program. "We have developed a novel MRI-based method to detect and measure the extent of LA wall scarring and, potentially, predict the success of RF ablation in patients with atrial fibrillation."


In this study, Marrouche and his University of Utah colleagues developed a technique for using a non-invasive method called delayed-enhancement cardiovascular MRI (DE-CMRI) to create 3D images of the left atrium both before and after RF ablation in patients with atrial fibrillation. They processed and analysed these images using custom software tools and then used computer algorithms to calculate the extent of LA wall injury.


Marrouche and his colleagues found that all patients who underwent RF ablation showed evidence of left atrium wall injury on MRI three months after the procedure. The pattern of tissue injury correlated with the areas where the radiofrequency energy was applied during RF ablation, and thus, was presumed to reflect tissue scarring. Marrouche and his colleagues also found patients with a higher percentage of LA wall injury were more likely to be free of arrhythmia than patients with lower percentages, suggesting the degree of scarring is linked to the likelihood of success in the RF ablation procedure.


"DE-CMRI is an established method for evaluating the tissues of the heart after a heart attack," said Marrouche. "But performing DE-CMRI to detect left atrium wall injury is challenging because the wall of the left atrium is so thin."


The 3D technique used by Marrouche and his colleagues achieves a much greater imaging resolution than the two-dimensional technique typically used to evaluate the extent of tissue damage after a heart attack or in other cardiac disease processes. Marrouche and his colleagues also developed methods of processing the MRI images in order to visualise the entire volume of left atrium wall injury in 3D.


The novel visualisation technique and analysis developed by Marrouche and his colleagues potentially could help doctors improve planning for RF ablation procedures by making it easier to identify the heart muscle cells that need to be destroyed. Improved localisation and isolation of these heart muscle cells would likely lead to a reduction in the recurrence rate of AF.


"The benefit of 3D MRI is that it visualises the entire LA wall," said Marrouche. "And, it is safe and non-invasive, so it can be repeated without significant risk to the patient."




Add New Comment

Most popular


Persistent atrial fibrillation treatment with robotic navigation and contact force sensing shows promising results
Wednesday, 22 Oct 2014
An international multicentre registry evaluating the role of remote robotic navigation and contact force sensing in persistent atrial fibrillation (AF) treatment has found that, at one year, a higher ... Persistent atrial fibrillation treatment with robotic navigation and contact force sensing shows promising results

Abbott to acquire Topera and Advanced Cardiac Therapeutics
Wednesday, 29 Oct 2014
Abbott enters the catheter-based electrophysiology market with the announcement of an agreement to purchase Topera and the securement of the rights to purchase Advanced Cardiac Therapeutics (ACT). B... Abbott to acquire Topera and Advanced Cardiac Therapeutics

Novel protein in heart linked to ventricular arrhythmias
Thursday, 09 Oct 2014
Cardiovascular scientists in the USA have identified in mouse models a protein known as Purkinje cell protein-4 (Pcp4) as a regulator of the heart’s rhythm. Additionally, they have found that when ... Novel protein in heart linked to ventricular arrhythmias

Features


Highlights from ISCAT 2014
Thursday, 20 Nov 2014
Michel Haïssaguerre and Etienne M Aliot, chairmen of the International Symposium on Catheter Ablation Techniques (ISCAT; 15–17 October 2014, Paris, France), discuss the highlights of this year’s ... Highlights from ISCAT 2014

The challenge of catheter ablation in congenital heart disease patients
Thursday, 13 Nov 2014
Dominic Abrams (Division of Cardiac Electrophysiology, Boston Children’s Hospital, Boston, USA) writes on the importance of arrhythmia management in congenital heart disease patients and identifies ... The challenge of catheter ablation in congenital heart disease patients

Profiles


Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions